Coronavirus Structure, Genome, Replication, Symptoms, Pathogenesis, and Prevention

Structure of Coronavirus

• Coronaviruses (enveloped RNA viruses) fall in the virus family Coronaviridae, order Nidovirales.
• They are enveloped, 120–160 nm particles containing an unsegmented genome of single-stranded positive-sense RNA (27–32 kb).
• The large plus-stranded RNA genome associates with the N protein (nucleocapsid protein) to form a helical nucleocapsid, 9–11 nm in diameter.
• Spike projections: 20 nm long, club- or petal-shaped, widely spaced on the envelope, giving a “solar corona” appearance.
• Viral structural proteins:
• Nucleocapsid (N) protein (50–60 kDa, phosphorylated)
• Membrane (M) glycoprotein (20–35 kDa, matrix protein, interacts with nucleocapsid)
• Spike (S) glycoprotein (180–220 kDa, forms petal-shaped peplomers)
• Some viruses (e.g., HCoV-OC43) also have HE glycoprotein (65 kDa) causing hemagglutination (clumping of red blood cells) and possessing acetylesterase activity.

Genome of Coronavirus

• Coronavirus genomes are monopartite, single-stranded, positive-sense, polyadenylated, and capped RNAs of 27–32 kb.
• The 5′ end (~20–22 kb) carries the replicase gene, encoding multiple enzymatic activities.
• Replicase gene products: encoded within ORFs 1a and 1b (open reading frames).
• Order of structural genes: Pol-S-E-M-N (Polymerase, Spike, Envelope, Membrane, Nucleocapsid).
• Additional ORFs encode 2–4 nonstructural proteins of unknown function.
• Intergenic sequence (IS): ~7 bases at the 5′ end of each gene, essential for subgenomic RNA formation.
• Infected cells contain overlapping subgenomic, capped, and polyadenylated mRNAs.
• Each subgenomic mRNA and genomic RNA is translated to produce only the protein encoded by the 5′ gene.

Epidemiology of Coronavirus

• Natural outbreaks of coronavirus-caused colds occur mostly in winter.
• Coronaviruses cause 15–30% of all colds.
• HCoV 229E, OC43, NL63 are found worldwide.
• Contribution of each HCoV varies yearly: e.g., 229E can account for 1%–35% of acute respiratory infections.
• Incidence fluctuates: one 3-year study showed 1%–35% infection rates.

Replication of Coronavirus

• Human infection occurs via respiratory secretions.
• Attachment: mediated by S glycoproteins binding to host cell receptors.
• Entry: fusion of viral envelope with host membrane or receptor-mediated endocytosis.
• 229E and NL63 bind aminopeptidase N and ACE-2, respectively.
• Receptors for OC43 and HKU-1 are unknown.

• Fusion: mediated by S2 portion of spike protein (class 1 fusion protein).
• Translation of genomic RNA → large polyprotein → processed into RNA-dependent RNA polymerase (RdRp).
• RdRp synthesizes a negative-strand RNA, template for nested set of subgenomic mRNAs.
• Translation of subgenomic mRNAs → structural proteins.
• N protein + genomic RNA → helical nucleocapsids.
• Membrane glycoprotein M: inserted into ER, anchored in Golgi apparatus.
• Nucleocapsid + M protein assemble at budding compartment (ERGIC).
• E and M proteins trigger virion budding, enclosing nucleocapsid.

Pathogenesis of Coronavirus

• Primary route of transmission: via the respiratory tract, spread by aerosols and large droplets (e.g., sneezes).
• Infection with common-cold coronaviruses causes ciliostasis (loss of ciliary action) and degenerative changes in respiratory epithelial cilia.
• Infection is usually localized to the upper respiratory tract because the optimum viral growth temperature is 33–35°C, though it may extend to the lower respiratory tract in some cases.
• HCoV-OC43 generally causes mild upper respiratory infections, but may exhibit neuroinvasive properties.

Clinical Manifestations of Coronavirus

• HCoVs in the 229E- and OC43-related serogroups cause upper respiratory symptoms in adults and children, varying in frequency and severity.
• Respiratory infections include bronchiolitis and pneumonia; gastroenteritis and neurological disorders can also occur.
• In adults, HCoVs usually cause “common colds”, often afebrile.
• Symptoms: nasal discharge, malaise, rhinorrhea, headache, chills, sore throat, cough.
• Incubation period: 2–5 days.
• Duration of symptoms: mean of 7 days (range 3–18 days).
• Immune response: rise in neutralizing and complement fixation antibodies, which wane over months.
• Lower respiratory tract involvement is rare, but pneumonia may occur.
• Asthmatic children may experience wheezing, and adults with chronic pulmonary disease may have worsened respiratory symptoms.
• HCoV-OC43 can infect neurons, potentially causing encephalitis.

Laboratory Diagnosis of Coronavirus

• Specimens: respiratory secretions, stool (for HKU1).
• Virus isolation:
• HUH7 human hepatoma cell line for OC43, 229E, HKU-1.
• LLC-MK2 and Vero B4 cells for NL63.
• Molecular detection: RT-PCR for viral RNA.
• Electron microscopy (EM): detection in negatively stained stool for enteric coronaviruses.
• Serology: complement fixation, ELISA, immunofluorescence, or virus neutralization tests.
• Passive hemagglutination test: detects antibodies to strain 229E.
• Hemagglutination and acetyl esterase assays: detect HCoV-OC43 virions expressing HE glycoprotein.

Treatment of Coronavirus

• No proven antiviral treatment.
• No vaccine currently available for human coronaviruses.

Prevention and Control of Coronavirus

• Frequent handwashing with soap and water.
• Avoid touching eyes, nose, or mouth with unwashed hands.
• Avoid close contact with sick individuals.
• Cover mouth and nose with a tissue when coughing or sneezing; dispose of the tissue properly and wash hands afterward.